SCHEMBL25698378

SCHEMBL25698378

NCCCNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 3/20 0.72
P2RX2 Q9UBL9 3/20 0.72
DNPH1 O43598 5/20 0.71
P2RY1 P47900 4/20 0.69
P2RY2 P41231 3/20 0.69
TAS1R3 Q7RTX0 2/20 0.69
TAS1R1 Q7RTX1 2/20 0.69
SRC P12931 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
PRKAB2 O43741 1/20 0.69
TRPM2 O94759 1/20 0.69
LDHA P00338 1/20 0.69
ADRB2 P07550 1/20 0.69
FBP1 P09467 1/20 0.69
ADORA1 P30542 1/20 0.69
PRKAG1 P54619 1/20 0.69
PRKAA2 P54646 1/20 0.69
PDE4D Q08499 1/20 0.69
KCNH2 Q12809 1/20 0.69
PRKAA1 Q13131 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20705924 1.00 P2RX3 (0.72) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL4820076 0.97 P2RX3 (0.71) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL216645 0.96 P2RX3 (0.70) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL4820592 0.95 DNPH1 (0.73) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL15305350 0.94 P2RX3 (0.67) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL14948866 0.93 P2RX3 (0.66) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL14946186 0.92 TAS1R3 (0.65) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL6707298 0.91 DNPH1 (0.68) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL4208216 0.90 P2RX3 (0.84) P2RX3P2RX2DNPH1P2RY1P2RY2
SCHEMBL30853828 0.89 P2RX3 (0.82) P2RX3P2RX2DNPH1P2RY1P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11684676-B2 Site-specific antibody-drug conjugates by ADP-ribosyl cyclases UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2023-06-27 US disclosed
US-20230128344-A1 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684676-B2 Site-specific antibody-drug conjugates by ADP-ribosyl cyclases CD38, SARM1, NT5C2 P2RX3 2636/4885P2RX2 2385/4885DNPH1 106/4885
US-20230128344-A1 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASES CD38, SARM1, NT5C2 P2RX3 2636/4885P2RX2 2385/4885DNPH1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.